PCM
ACET icon

Prelude Capital Management’s Adicet Bio ACET Stock Holding History

Prelude Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,140
Closed -$25.9K – 982
2025
Q1 		$25.9K Buy
2,140
+333
+18% +$4.76K ﹤0.01% 1122
2024
Q4 		$27.8K Sell
1,807
-692
-28% -$13.1K ﹤0.01% 1169
2024
Q3 		$57.6K Buy
+2,499
New +$55.9K ﹤0.01% 1204
2024
Q2 		– Sell
-1,738
Closed -$65.4K – 1186
2024
Q1 		$65.4K Buy
+1,738
New +$71.9K ﹤0.01% 1239
2020
Q3 		– Sell
-21
Closed -$5K – 1762
2020
Q2 		$5K Buy
+21
New +$4.13K ﹤0.01% 1706

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Prelude Capital Management's ACET Position: Q2 2025 in Review

Prelude Capital Management sold out of Adicet Bio (ACET) in Q2 2025, closing a stake of 2,140 shares — an estimated $25.9K sold.

Prelude Capital Management first reported a position in ACET in Q2 2020 and held it in 5 quarters. The position peaked at $65.4K in Q1 2024. 49 funds tracked by Wall St. Rank hold ACET as of Q2 2025.

  • Prelude Capital Management reported no remaining Adicet Bio position as of Q2 2025 after selling out during the quarter.
  • Prelude Capital Management sold 2,140 Adicet Bio shares in Q2 2025, an estimated $25.9K.
  • Prelude Capital Management first reported a position in Adicet Bio in Q2 2020 and held it in 5 quarters.
  • Prelude Capital Management's Adicet Bio position peaked at $65.4K in Q1 2024.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.